{"schema_version":"secwatch.filing_event.v1","accession":"0001157523-23-000973","form_type":"8-K","ticker":"ALDX","cik":"0001341235","company_name":"Aldeyra Therapeutics, Inc.","filed_at":"2023-06-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.506496+00:00","generated_at":"2026-06-13T23:54:49.650086+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Aldeyra announces positive Phase 3 INVIGORATE-2 trial for reproxalap in allergic conjunctivitis","bullets":["Primary endpoint met: ocular itching reduction at all 11 timepoints (p<0.0001).","Key secondary endpoint ocular redness achieved (p=0.004); tearing and total severity score also significant (p<0.0001).","Results consistent with prior trials; no safety concerns; 130 of 131 patients completed.","Reproxalap NDA for dry eye disease under FDA review with PDUFA date of November 23, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001157523-23-000973","json":"https://secwatch.observer/filing/0001157523-23-000973.json","markdown":"https://secwatch.observer/filing/0001157523-23-000973.md","text":"https://secwatch.observer/filing/0001157523-23-000973.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1341235/000115752323000973/0001157523-23-000973-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1341235/000115752323000973/a53421176.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T23:54:49.650086+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}